MRTX
Income statement / Annual
Last year (2022), Mirati Therapeutics, Inc.'s total revenue was $12.44 M,
a decrease of 82.75% from the previous year.
In 2022, Mirati Therapeutics, Inc.'s net income was -$740.87 M.
See Mirati Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$12.44 M |
$72.09 M |
$13.40 M |
$3.34 M |
$12.93 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$600.00 K
|
$1.78 M
|
$299.35 M
|
$182.87 M
|
$93.87 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$11.84 M
|
-$436.50 M
|
-$285.95 M
|
-$179.53 M
|
-$80.95 M
|
-$58.09 M
|
-$68.49 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.95
|
-6.05
|
-21.34
|
-53.83
|
-6.26
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$531.63 M
|
$508.59 M
|
$299.35 M
|
$182.87 M
|
$93.87 M
|
$58.09 M
|
$68.49 M
|
$48.96 M
|
$26.07 M
|
$19.80 M
|
| General & Administrative Expenses |
$0.00
|
$136.68 M
|
$83.41 M
|
$42.57 M
|
$21.68 M
|
$13.45 M
|
$15.29 M
|
$15.76 M
|
$12.70 M
|
$11.14 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$239.80 M
|
$136.68 M
|
$83.41 M
|
$42.57 M
|
$21.68 M
|
$13.45 M
|
$15.29 M
|
$15.76 M
|
$12.70 M
|
$11.14 M
|
| Other Expenses |
$0.00
|
-$5.30 M
|
$11.43 M
|
$8.85 M
|
$4.21 M
|
$0.00
|
$661.00 K
|
$170.00 K
|
$334.00 K
|
$1.03 M
|
| Operating Expenses |
$771.43 M
|
$645.27 M
|
$382.76 M
|
$33.73 M
|
$115.55 M
|
$71.54 M
|
$83.78 M
|
$64.71 M
|
$38.77 M
|
$31.97 M
|
| Cost And Expenses |
$772.03 M
|
$645.27 M
|
$382.76 M
|
$225.44 M
|
$115.55 M
|
$71.54 M
|
$83.78 M
|
$64.71 M
|
$38.77 M
|
$30.94 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$203.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$203.00 K
|
| Depreciation & Amortization |
$2.93 M
|
$1.78 M
|
$641.00 K
|
$249.00 K
|
$175.00 K
|
$184.00 K
|
$180.00 K
|
$212.00 K
|
$199.00 K
|
$171.00 K
|
| EBITDA |
-$756.66 M |
-$571.40 M |
-$368.72 M |
-$221.86 M |
-$102.63 M |
-$71.54 M |
-$83.78 M |
-$64.71 M |
$2.01 M |
-$31.97 M |
| EBITDA Ratio |
-60.84
|
-7.93
|
-27.52
|
-66.52
|
-7.94
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-61.08
|
-7.95
|
-27.57
|
-66.6
|
-7.94
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$19.23 M
|
-$5.30 M
|
$11.43 M
|
$8.85 M
|
$4.21 M
|
$1.11 M
|
$661.00 K
|
$170.00 K
|
-$45.71 M
|
-$21.91 M
|
| Income Before Tax |
-$740.36 M
|
-$578.49 M
|
-$357.94 M
|
-$213.26 M
|
-$98.42 M
|
-$70.43 M
|
-$83.12 M
|
-$64.54 M
|
-$43.70 M
|
-$52.88 M
|
| Income Before Tax Ratio |
-59.53
|
-8.02
|
-26.72
|
-63.94
|
-7.61
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$508.00 K
|
$3.30 M
|
-$511.00 K
|
-$659.00 K
|
$0.00
|
-$130.00 K
|
-$155.00 K
|
-$249.00 K
|
$121.00 K
|
-$23.00 K
|
| Net Income |
-$740.87 M
|
-$581.78 M
|
-$357.94 M
|
-$213.26 M
|
-$98.42 M
|
-$70.43 M
|
-$83.12 M
|
-$64.54 M
|
-$43.68 M
|
-$52.87 M
|
| Net Income Ratio |
-59.57
|
-8.07
|
-26.72
|
-63.94
|
-7.61
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-13.18 |
-11.21 |
-7.96 |
-5.69 |
-3.19 |
-2.79 |
-4.2 |
-3.82 |
-3.24 |
-4.78 |
| EPS Diluted |
-13.18 |
-11.21 |
-7.96 |
-5.69 |
-3.19 |
-2.79 |
-4.2 |
-3.82 |
-3.24 |
-4.78 |
| Weighted Average Shares Out |
$56.23 M
|
$51.88 M
|
$44.99 M
|
$37.47 M
|
$30.90 M
|
$25.29 M
|
$19.79 M
|
$16.90 M
|
$13.48 M
|
$11.06 M
|
| Weighted Average Shares Out Diluted |
$56.23 M
|
$51.88 M
|
$44.99 M
|
$37.47 M
|
$30.90 M
|
$25.29 M
|
$19.79 M
|
$16.90 M
|
$13.48 M
|
$11.06 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
